Literature DB >> 9402916

When at first you don't succeed: sequential strategies for antidepressant nonresponders.

M E Thase1, A J Rush.   

Abstract

Now, more than ever before, a wealth of options exists for depressed patients who do not benefit from treatment with standard, first-line antidepressant agents. In this paper, alternate antidepressant strategies are reviewed within the context of a five-stage strategy, ranging from lesser to greater degrees of treatment resistance. The overall strategy recommended progresses from simpler (i.e., an alternate monotherapy) to more complex strategies (i.e., combination or augmentation regimens), with the nonselective monoamine oxidase inhibitors (+/- lithium salts) and electroconvulsive therapy typically reserved for treatment of Stages III and IV of resistance, respectively. Psychotherapeutic management also is an important ingredient in the ongoing treatment of these patients, particularly to counteract the demoralization and frustration that understandably accompany the failure to respond to so many treatments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402916

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  122 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

Review 2.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

3.  A Case of Electroconvulsive Therapy-Resistant Depression Responding to Multiple Dopaminergic Medications.

Authors:  Maju Mathew Koola; Jan A Fawcett
Journal:  Prim Care Companion CNS Disord       Date:  2015-04-30

Review 4.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Dextroamphetamine and Pramipexole Combination for Treatment-Resistant Unipolar Depression.

Authors:  Maju Mathew Koola; Jan Fawcett
Journal:  Psychiatr Ann       Date:  2016-08-12

Review 6.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

7.  Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.

Authors:  Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Stefan Unterecker; Christoph Hiemke; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-01       Impact factor: 5.270

8.  What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis.

Authors:  Nhu N Huynh; Roger S McIntyre
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

9.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 10.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.